Amgen Gains as Sjogren's Drug Clears Phase 3

Amgen NASDAQ:AMGN, the biotechnology company, said its experimental Sjogren's disease drug dazodalibep met the main goal of a Phase 3 trial. Shares rose about 0.2% to $406.85 at 11.14am ET time on Thursday. The trial news is promising, but the stock's modest move suggests investors want the full da…